IRVINE, Calif., April 11, 2019 /PRNewswire/ -- Cryoport,
Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Company"), the world's
leading temperature-controlled logistics company dedicated to the
life sciences industry, today announced it has been selected by
Celularity, a world leading allogeneic cell therapy company, to
utilize its complete range of temperature-controlled solutions.
Cryoport is the life sciences industry's foremost
temperature-controlled logistics provider, supporting over 357
clinical trials globally as well as blockbuster FDA-approved CAR-T
therapies from Novartis and Gilead.
Celularity is a clinical-stage cell therapeutics company
developing allogeneic cellular therapies harnessed from human
placentas through its proprietary IMPACT™ platform across
immuno-oncology, inflammatory & age-related diseases. The
agreement will give Celularity access to Cryoport's full suite of
temperature-controlled logistics solutions, including the Cryoport
Express® shippers, the industry-leading Cryoportal® Logistics
Management Platform, Smartpak II™ Condition Monitoring System and
24/7/365 logistics support.
Jerrell Shelton, Chief Executive
Officer of Cryoport, said, "We are proud to support Celularity's
clinical programs for the development of transformative allogeneic
cell therapies. Cryoport's end-to-end, industry-leading,
temperature-controlled logistics solutions protect the biologic
commodities that underpin these potentially ground-breaking
therapies and play a vital role in their development."
John R. Haines, Chief
Administrative Officer of Celularity, said, "Celularity's IMPACT™
platform seamlessly integrates biosourcing through advanced cell
manufacturing and productization of allogeneic placental-derived
cell therapeutics. Industry-leading supply chain management tools
are critical to our ability to deliver transformative, on-demand,
off-the-shelf therapeutic options to patients in the United States and worldwide. We look
forward to partnering with Cryoport for cell therapy product
logistics management."
About Celularity, Inc.
Celularity, headquartered in
Warren, New Jersey, is a
clinical-stage cell therapeutics company delivering transformative
allogeneic cellular therapies, engineered from the postpartum human
placenta. Using proprietary technology in combination with its
IMPACTTM platform, Celularity is the only company to harness the
versatility of placenta-derived cells ashighly scalable,
off-the-shelf treatments for patients with cancer, inflammatory and
age-related diseases. To learn more, please visit
www.celularity.com.
About Cryoport, Inc.
Cryoport is a trusted global
provider of temperature-controlled logistics solutions for life
sciences commodities during distribution, serving the
biopharmaceutical market with leading-edge logistics solutions for
biologic materials, such as regenerative medicine, including
immunotherapies, stem cells and CAR-T cells. Cryoport's solutions
are used by points-of-care, CRO's, central laboratories,
pharmaceutical companies, manufacturers, university researchers et
al; as well as the reproductive medicine market, primarily in IVF
and surrogacy; and the animal health market, primarily in the areas
of vaccines and reproduction. Cryoport's proprietary Cryoport
Express® Shippers, Cryoportal® Logistics Management
Platform, leading-edge SmartPak II™ Condition Monitoring System and
geo-sensing technology, paired with unparalleled cold chain
logistics expertise and 24/7 client support, make Cryoport the
end-to-end cold chain logistics partner that the industry
trusts.
Cryoport is dedicated to: simplifying global cold chain
logistics through innovative technology, unmatched monitoring and
data capture and support, including consulting; delivering the most
advanced temperature-controlled logistics solutions for the life
sciences industry; and providing vital information that provides
peace of mind throughout the life of each logistics process.
For more information, visit www.cryoport.com. Sign up to follow
@cryoport on Twitter at www.twitter.com/cryoport.
Forward Looking Statements
Statements in
this news release which are not purely historical, including
statements regarding Cryoport, Inc.'s intentions, hopes, beliefs,
expectations, representations, projections, plans or predictions of
the future are forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. It is important
to note that the Company's actual results could differ materially
from those in any such forward-looking statements. Factors that
could cause actual results to differ materially include, but are
not limited to, risks and uncertainties associated with the effect
of changing economic conditions, trends in the products markets,
variations in the Company's cash flow, market acceptance risks, and
technical development risks. The Company's business could be
affected by a number of other factors, including the risk factors
listed from time to time in the Company's SEC reports including,
but not limited to, the Company's 10-K for the year ended
December 31, 2018 filed with the SEC.
The Company cautions investors not to place undue reliance on the
forward-looking statements contained in this press release.
Cryoport, Inc. disclaims any obligation, and does not undertake to
update or revise any forward-looking statements in this press
release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/celularity-selects-cryoports-temperature-controlled-logistics-solutions-300830412.html
SOURCE Cryoport, Inc.